LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

LLY

1,014.98

-0.96%↓

JNJ

240.9

+1.12%↑

ABBV

220.69

-0.72%↓

NVS

159.71

+1.01%↑

MRK

119.32

+1.9%↑

Search

Harvard Bioscience Inc

Fermé

SecteurSoins de santé

0.54 -8.47

Résumé

Variation du prix de l'action

24h

Actuel

Min

0.53

Max

0.6

Chiffres clés

By Trading Economics

Revenu

1.1M

-1.2M

Ventes

141K

21M

Marge bénéficiaire

-5.978

Employés

330

EBITDA

1M

1.2M

Dividendes

By Dow Jones

Prochains Résultats

12 mars 2026

Statistiques du Marché

By TradingEconomics

Capitalisation Boursière

-1.9M

24M

Ouverture précédente

9.01

Clôture précédente

0.54

Sentiment de l'Actualité

By Acuity

17%

83%

23 / 352 Classement par Healthcare

Score Technique

By Trading Central

Confiance

Weak Bearish Evidence

Harvard Bioscience Inc Graphique

Les performances passées ne sont pas un indicateur fiable des résultats futurs.

Actualités Associées

11 févr. 2026, 23:47 UTC

Actions en Tendance

Stocks to Watch: AppLovin, Cisco, Cognex, Pilgrim's Pride

11 févr. 2026, 22:59 UTC

Résultats
Acquisitions, Fusions, Rachats

Grab Holdings to Buy U.S.-Based Stash Financial

11 févr. 2026, 23:54 UTC

Résultats

McDonald's Says Its Value Campaign Is Paying Off -- 2nd Update

11 févr. 2026, 23:50 UTC

Market Talk

Global Equities Roundup: Market Talk

11 févr. 2026, 23:50 UTC

Market Talk

Nikkei May Rise on Hopes for Takaichi's Economic Steps -- Market Talk

11 févr. 2026, 23:49 UTC

Résultats

Singtel: Key Focus Areas Are Strengthening Core Businesses, Scaling Growth Engines, Building Momentum Across Regional Associates >Z74.SG

11 févr. 2026, 23:45 UTC

Résultats

Singtel: Net Exceptional Gain of S$1.15B in 3Q Primarily From Sale of Partial Stake in Bharti Airtel>Z74.SG

11 févr. 2026, 23:42 UTC

Résultats

Singtel 3Q Underlying Net Profit S$744M Vs. S$680M >Z74.SG

11 févr. 2026, 23:41 UTC

Résultats

Singtel 3Q Net S$1.89B Vs. Net S$1.32B >Z74.SG

11 févr. 2026, 23:40 UTC

Résultats

Singtel 3Q Operating Revenue S$3.66B Vs. S$3.63B >Z74.SG

11 févr. 2026, 23:35 UTC

Market Talk

Gold Falls on Prospects of Long Fed Pause -- Market Talk

11 févr. 2026, 23:18 UTC

Market Talk

AppLovin CEO Looks to Soothe Concerns Over AI, Competition -- Market Talk

11 févr. 2026, 23:14 UTC

Market Talk

RBA Governor Faces Barrage of Questions About Govt Spending -- Market Talk

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Net KRW525.72B Vs. Loss KRW161.87B >035720.SE

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Oper Pft KRW732.04B Vs. Pft KRW460.21B >035720.SE

11 févr. 2026, 22:59 UTC

Résultats

Kakao 2025 Rev KRW8.099T Vs. KRW7.872T >035720.SE

11 févr. 2026, 22:58 UTC

Résultats

Kakao 4Q Net Loss Missed FactSet-Compiled Consensus

11 févr. 2026, 22:57 UTC

Résultats

Kakao 4Q Loss KRW39.30B Vs. Loss KRW395.21B >035720.SE

11 févr. 2026, 22:54 UTC

Résultats

Kakao 4Q Oper Pft KRW203.45B Vs. Pft KRW75.43B >035720.SE

11 févr. 2026, 22:53 UTC

Résultats

Kakao 4Q Rev KRW2.133T Vs. KRW1.957T >035720.SE

11 févr. 2026, 22:47 UTC

Résultats

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 févr. 2026, 22:47 UTC

Résultats

AppLovin Reports Strong Earnings. The Stock Is Down. -- Barrons.com

11 févr. 2026, 22:23 UTC

Résultats

Grab Holdings Expects to Close Stash Acquisition in 3Q of 2026 >GRAB

11 févr. 2026, 22:22 UTC

Résultats

Grab Holdings to Acquire U.S. Digital Financial Services Company Stash Financial >GRAB

11 févr. 2026, 22:22 UTC

Résultats

Grab Holdings Sees FY26 Adj Ebitda $700M to $720M >GRAB

11 févr. 2026, 22:19 UTC

Résultats

Grab Holdings Sees FY26 Rev $4.04B to $4.10B >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Adj Ebitda $148.0M Vs. $97.0M >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Net $153.0M Vs. Net $11.0M >GRAB

11 févr. 2026, 22:18 UTC

Résultats

Grab Holdings 4Q Oper Pft $52.0M Vs. $2.0M >GRAB

11 févr. 2026, 22:16 UTC

Résultats

Grab Holdings 4Q Rev $906.0M Vs. $764.0M >GRAB

Comparaison

Variation de prix

Harvard Bioscience Inc prévision

Note du Consensus

By TipRanks

0 ratings

0

Achat

0

Maintien

0

Vente

Score Technique

By Trading Central

0.3 / 0.3401Support & Résistance

Court Terme

Weak Bearish Evidence

Moyen Terme

No Evidence

Long Terme

No Evidence

Sentiment

By Acuity

23 / 352Classement par Soins de santé

Sentiment de l'Actualité

Très Fortes Indications Haussières

Volatilité

Inférieur à la moyenne

Changement du Volume d'Actualités (RCV)

Supérieur à la moyenne

Éléments financiers

Frais Généraux et Administratifs

Dépenses d'exploitation

Résultat avant impôt

Ventes

Coût des ventes

Marge brute des ventes

Charges d'intérêt sur la dette

EBITDA

Bénéfice d'exploitation

$

À Propos Harvard Bioscience Inc

Harvard Bioscience, Inc. develops, manufactures, and sells technologies, products, and services for life science applications in the United States and internationally. The company offers cellular and molecular technology products, such as syringe and peristaltic infusion pump products; electroporation and electrofusion instruments, amino acid analyzers, spectrophotometers, and other equipment for molecular level testing and research; and precision scientific measuring instrumentation and equipment, including data acquisition systems for cellular analysis, complete micro electrode array solutions for in vivo recordings, and in vitro systems for extracellular recordings. It also provides preclinical products that includes platform to assess physiological data from organisms for research, drug discovery, and drug development services comprising implantable and externally worn telemetry systems for use in research to collect cardiovascular, central nervous system, respiratory, and metabolic data; behavioral products; isolated organ and surgical products, instruments and accessories for tissue, and organ-based lab research, including surgical products, infusion systems, and behavior research systems; turn-key respiratory system solutions, including plethysmograph chambers, data acquisition hardware, physiological signal analysis software, and final report generation; inhalation and exposure systems; and GLP-capable data acquisition and analysis systems. The company markets its products through sales organizations, websites, and distributors to research scientists in pharmaceutical and biotechnology companies, universities, hospitals, and government laboratories; and contract research organizations and academic labs. It primarily sells its products under Harvard Apparatus, DSI, Buxco, Biochrom, BTX, Heka, Hugo Sachs, Multichannel Systems MCS GmbH, and Panlab brands. Harvard Bioscience, Inc. was founded in 1901 and is based in Holliston, Massachusetts.
help-icon Live chat